Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CCL3 (MIP-1 alpha) Mouse anti-Human, FITC, Clone: CR3M, eBioscience™ Non-distribution product as customer accommodation.

Mouse Monoclonal Antibody

$301.00

Specifications

Antigen CCL3 (MIP-1 alpha)
Clone CR3M
Target Species Human
Conjugate FITC
Isotype IgG1, kappa
View More Specs

Products 1
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
50-112-2181 Non-distribution product as customer accommodation.
View Documents
Invitrogen
11970642
100 Tests
Each for $301.00
Add to cart
 
Description

Description

Description: This CR3M monoclonal antibody reacts with human CCL3. CCL3, also known as MIP-1 alpha (Macrophage Inflammatory Protein 1 alpha), is a member of the CC- subfamily of chemokines and is most closely related to CCL4, or MIP-1 beta. These proteins play critical roles in the recruitment of leukocytes to the site of inflammation. While both CCL3 and CCL4 will attract monocytes, macrophages, and dendritic cells, CCL3 preferentially attracts CD8+ T cells, while CD4+ T cells are more responsive to CCL4. In addition to its chemotactic functions, CCL3 induces inflammatory cytokine secretion, mast cell degranulation, and NK cell activation. It has also been reported to inhibit hematopoetic stem cell proliferation and may be responsible for the maintece of these cells in a quiescent state. CCL3 signaling is mediated by the G protein-coupled receptors CCR1, CCR4, and CCR5, which are shared with CCL4 and CCL5 (RANTES). CCR5 is the primary co-receptor for HIV entry, which the virus binds through the gp120 envelope protein. All CCR5 ligands demonstrate potent inhibition of virus entry into the cell, both through steric hindrance of gp120-CCR5 interaction, and ligand-mediated receptor internalization. This CR3M clone is specific to CCL3, with no detectable cross-reactivity to Human CCL4 (MIP-1 beta). Applications Reported: This CR3M antibody has been reported for use in intracellular staining followed by flow cytometric analysis.

Applications Tested: This CR3M antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis of stimulated normal human peripheral blood cells using the Intracellular Fixation & Permeabilization Buffer Set (cat. 88-8824) and protocol. Please refer to Best Protocols: Protocol A: Two step protocol for (cytoplasmic) intracellular proteins located under the Resources Tab online. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 µm post-manufacturing filtered. Macrophage inflammatory protein-1a (MIP-1a) is an 8kDa member of the C-C chemokine subfamily. C-C chemokines are chemoattractants and activators for monocytes and T cells. MIP-1a has been identified as one of the major HIV-SFs produced by CD8+ T cells, along with MIP-1b and RANTES.
Specifications

Specifications

CCL3 (MIP-1 alpha)
Human
IgG1, kappa
Monoclonal
Liquid
Antibody
4° C, store in dark, DO NOT FREEZE!
CR3M
FITC
Flow Cytometry
Primary
Monoclonal
PBS with 0.1% gelatin, 0.2% BSA and 0.09% sodium azide; pH 7.2
RUO
SDS

For Research Use Only.

Provide Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit